Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?

Menopause is often accompanied by vasomotor symptoms that negatively impact daily functioning and overall well-being. Hormone therapy remains the gold standard for relief; however, contraindications and patient preferences may limit its use. To address this gap, nonhormonal therapies have been developed and investigated. Two newer options, fezolinetant and elinzanetant, directly target hypothalamic pathways involved in thermoregulation through modulation of neurokinin B. Clinical studies of these selective neurokinin B receptor antagonists demonstrate reduced frequency of vasomotor symptoms with their use, positioning them as promising options for individuals who are unable or unwilling to pursue hormone-based treatment.